Cargando…
Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication
INTRODUCTION: Prevalence of type 2 diabetes (T2D) is increasing rapidly and lifestyle interventions to reverse diabetes are seen as a possible solution to stop this trend. New practice-based evidence is needed to gain more insight in the actual, and above all scientific, basis for these claims. METH...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678479/ https://www.ncbi.nlm.nih.gov/pubmed/33235957 http://dx.doi.org/10.1136/bmjnph-2018-000012 |
_version_ | 1783612164264689664 |
---|---|
author | Pot, Gerda K Battjes-Fries, Marieke CE Patijn, Olga N Pijl, Hanno Witkamp, Renger F de Visser, Marianne van der Zijl, Nynke de Vries, Maaike Voshol, Peter J |
author_facet | Pot, Gerda K Battjes-Fries, Marieke CE Patijn, Olga N Pijl, Hanno Witkamp, Renger F de Visser, Marianne van der Zijl, Nynke de Vries, Maaike Voshol, Peter J |
author_sort | Pot, Gerda K |
collection | PubMed |
description | INTRODUCTION: Prevalence of type 2 diabetes (T2D) is increasing rapidly and lifestyle interventions to reverse diabetes are seen as a possible solution to stop this trend. New practice-based evidence is needed to gain more insight in the actual, and above all scientific, basis for these claims. METHODS: This observational study with a pretest post-test design aimed to pilot a 6-month multicomponent outpatient group-based nutrition and lifestyle intervention programme on glycaemic control and use of glucose lowering medication in motivated T2D patients with a body mass index (BMI) >25 kg/m(2) in the Netherlands (February 2015–March 2016). RESULTS: 74 T2D patients (56% female) aged 57.4±8.0 years with mean BMI 31.2±4.2 kg/m(2) and mean waist circumference 105.4±10.2 cm were included in the study. Compared with baseline, mean HbA1c levels at 6 months were 5 mmol/mol lower (SD=10, p<0.001) and the number of participants with HbA1c levels ≤53 mmol/mol after intervention had increased (from 36% (n=26/72) to 60% (n=43/72)). At baseline, 90% of participants were taking at least one type of glucose lowering medication. At 6 months, 49% (n=35/72) of the participants had reduced their medication or eliminated it completely (13%). Secondary outcomes were significantly lower fasting glucose levels (− 1.2±2.6 mmol/L), body weight (−4.9±5.1 kg), BMI (−1.70±1.69 kg/m(2)) and waist circumference (−9.4±5.0 cm). Plasma lipids remained unchanged except for a decrease in triglyceride levels. Furthermore, self-reported quality of life was significantly higher while experienced fatigue and sleep problems were significantly lower. CONCLUSION: This pilot study showed that a 6-month multicomponent group-based program in a routine care setting could improve glycaemic control and reduce the use of glucose lowering medication in motivated T2D diabetics. A fully scaled study is needed to confirm these results. |
format | Online Article Text |
id | pubmed-7678479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-76784792020-11-23 Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication Pot, Gerda K Battjes-Fries, Marieke CE Patijn, Olga N Pijl, Hanno Witkamp, Renger F de Visser, Marianne van der Zijl, Nynke de Vries, Maaike Voshol, Peter J BMJ Nutr Prev Health Original Research INTRODUCTION: Prevalence of type 2 diabetes (T2D) is increasing rapidly and lifestyle interventions to reverse diabetes are seen as a possible solution to stop this trend. New practice-based evidence is needed to gain more insight in the actual, and above all scientific, basis for these claims. METHODS: This observational study with a pretest post-test design aimed to pilot a 6-month multicomponent outpatient group-based nutrition and lifestyle intervention programme on glycaemic control and use of glucose lowering medication in motivated T2D patients with a body mass index (BMI) >25 kg/m(2) in the Netherlands (February 2015–March 2016). RESULTS: 74 T2D patients (56% female) aged 57.4±8.0 years with mean BMI 31.2±4.2 kg/m(2) and mean waist circumference 105.4±10.2 cm were included in the study. Compared with baseline, mean HbA1c levels at 6 months were 5 mmol/mol lower (SD=10, p<0.001) and the number of participants with HbA1c levels ≤53 mmol/mol after intervention had increased (from 36% (n=26/72) to 60% (n=43/72)). At baseline, 90% of participants were taking at least one type of glucose lowering medication. At 6 months, 49% (n=35/72) of the participants had reduced their medication or eliminated it completely (13%). Secondary outcomes were significantly lower fasting glucose levels (− 1.2±2.6 mmol/L), body weight (−4.9±5.1 kg), BMI (−1.70±1.69 kg/m(2)) and waist circumference (−9.4±5.0 cm). Plasma lipids remained unchanged except for a decrease in triglyceride levels. Furthermore, self-reported quality of life was significantly higher while experienced fatigue and sleep problems were significantly lower. CONCLUSION: This pilot study showed that a 6-month multicomponent group-based program in a routine care setting could improve glycaemic control and reduce the use of glucose lowering medication in motivated T2D diabetics. A fully scaled study is needed to confirm these results. BMJ Publishing Group 2019-05-14 /pmc/articles/PMC7678479/ /pubmed/33235957 http://dx.doi.org/10.1136/bmjnph-2018-000012 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Pot, Gerda K Battjes-Fries, Marieke CE Patijn, Olga N Pijl, Hanno Witkamp, Renger F de Visser, Marianne van der Zijl, Nynke de Vries, Maaike Voshol, Peter J Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title | Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title_full | Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title_fullStr | Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title_full_unstemmed | Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title_short | Nutrition and lifestyle intervention in type 2 diabetes: pilot study in the Netherlands showing improved glucose control and reduction in glucose lowering medication |
title_sort | nutrition and lifestyle intervention in type 2 diabetes: pilot study in the netherlands showing improved glucose control and reduction in glucose lowering medication |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678479/ https://www.ncbi.nlm.nih.gov/pubmed/33235957 http://dx.doi.org/10.1136/bmjnph-2018-000012 |
work_keys_str_mv | AT potgerdak nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT battjesfriesmariekece nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT patijnolgan nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT pijlhanno nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT witkamprengerf nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT devissermarianne nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT vanderzijlnynke nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT devriesmaaike nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication AT vosholpeterj nutritionandlifestyleinterventionintype2diabetespilotstudyinthenetherlandsshowingimprovedglucosecontrolandreductioninglucoseloweringmedication |